MK1084-014: A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab in Participants with KRAS G12C Mutant, Advanced Solid Tumors (KANDLELIT-014)

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT07209111?term=MK-1084-014&rank=1

Contact name

Laura Morse Cucci

Clinical trials study type

Oncology - Selected Cancers

Clinical trials trial status

Open to Accrual

IRB number

2381957

Principal investigator

Paul Celano, MD

Clinical trials study number

G2507

Phone

443-849-3122

Clinical trials title (full)

MK1084-014: A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab in Participants with KRAS G12C Mutant, Advanced Solid Tumors (KANDLELIT-014)